Skip to main content

Tweets

Pain sensitization in #OA in the MOST study. Biomechanical forces- ground reaction forces may Alter nociceptive signaling but was not associated with pain. Walking evoked knee pain specifically tested - no diff @RheumNow #ACR23 https://t.co/G7TXuwJ2EQ
Bella Mehta @bella_mehta ( View Tweet )
2 years 3 months ago
Tapering ABA vs. stable dose ABA in RA No diff in DAS28 remission at 2 years But… Only in patients receiving concomitant MTX Those tapering ABA mono also experience higher functional important Of note: not an RCT @RheumNow #ACR23 ABST2542 https://t.co/yycCDTnRiF
Aurelie Najm ( View Tweet )
2 years 3 months ago
#Lupus #nephritis - #inflammatory #fibrosis predicts #renal damage on #kidney #bx @ACRheum @RheumNow #ACR23 #2552 - similar in CRF from #Diabetes etc Biomarker is i-IFTA - same as other CRF diseases https://t.co/2LNn5Wn7rJ
Janet Pope ( View Tweet )
2 years 3 months ago
How does CAR-T work and how many do we have? Dr. Sadelain details the history, manufacturing, and 6 currently FDA-approved CAR-T products. #ACR23 @RheumNow https://t.co/a4jGfhT8EU
Dr. Rachel Tate ( View Tweet )
2 years 3 months ago
Dr. @drpnash @RheumNow ➡️Difficult to treat Axial SpA ; 23,0000 🧍‍♀️🧍: 1-Failure of 3 biolo - targ synth, or different mechanism of action. 2- Around 10% of patients. 1-Female. 2-Peripheral arthritis. 3-Psoriasis 4-Lipid , HTN, Smoking. https://t.co/B99TcXjjiF… #ACR23

Nouf Al hemmadi ( View Tweet )

2 years 3 months ago
Got to get a pic with the very busy man Dr ⁦@RheumNow⁩ John “Jack” Cush at his booth at @ACRheum #ACR23 #ACRambassador . Make sure to follow RheumNow to keep up on important rheum matters https://t.co/rgWvRr0Dln
Donald Thomas, MD @lupuscyclopedia ( View Tweet )
2 years 3 months ago
The ADIRA trial showed no significant difference in change in DAS28 bet grps in the adjusted analysis. Intervention included food delivery svc & probiotic shot Limitations included study design issues such small sample size #ACR23 @RheumNow @rheumarhyme https://t.co/J6LEb0yONS
sheila ( View Tweet )
2 years 3 months ago
Don’t forget: 👉anti-HMGCR Ab in patients with immune mediated necrotizing myositis (may be assc with statins) 👉Anti-synthetase Ab assc with ILD, anti-synthetase syndrome #Rheum #BoardQuestion https://t.co/pBAADeR9ON

TheDaoIndex @KDAO2011 ( View Tweet )

2 years 3 months ago
Persistence of IL-17i vs. TNFi in PsA treatment Large database study Persistence of IL-17i slightly greater than TNFi over 12 months Are IL-17i a better longterm strategy for PsA pts? @RheumNow #ACR23 Abs# 2240 https://t.co/9km5XgXcLE
Robert B Chao, MD ( View Tweet )
2 years 3 months ago
#VEXAS is still hot at #ACR23 - 245K whole genome sequencing data from #NIH All of US - 74 with somatic mutation UBA1 Increased asthma, Tietze’s syndrome and neutropenia Hemoglobin similar in cases and controls @rheumnow #abstL03 https://t.co/A374w60e6H
Bella Mehta @bella_mehta ( View Tweet )
2 years 3 months ago
Review of the limitations and possible toxicities with CAR-T treatment. ICANs and CRS, while treatable, are very important to educate and understand. This is part of the intersection of heme/onc and rheum. https://t.co/itbwLdHuqf

Dr. Rachel Tate ( View Tweet )

2 years 3 months ago
RheumNow’s expanded coverage of the #ACR23 is sponsored in part by Novartis. All content is chosen by RheumNow & its faculty.

Dr. John Cush @RheumNow ( View Tweet )

2 years 3 months ago
×